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A single course ofprenatal corticosteroids offers no benefits for infants born seven days after
treatment. Repeat corticosteroid treatment may improve health outcomes, but with possible
adverse effects. This thesis aimed to examine the effects of repeat prenatal corticosteroids on
infant growth and neurodevelopment.
Methods
Women at risk of preterm birth more than seven days after a single course of prenatal
corticosteroids, who gave informed written consent, were randomised to receive weekly repeat
dose corticosteroids or placebo, if still at risk, until 32 weeks gestation. Infant growth was
assessed at birth, day three, weekly to four weeks, monthly to four months of age atd at 7/¿
months corrected age (CA). Neurodevelopmental milestones were assessed at four and eight
months CA and noveltypreference aI7 % months CA
Results
One hundred and forty seven infants were randomised. Repeat corticosteroid treatment
reduced the weight z-score at birth, four months following birth and at 7Y+ months CA,
compared with placebo. Total body length z-score and knee-ankle length were reduced at
birth for repeat corticosteroid infants, compared with placebo. Total body length z-score was
unaffected by repeat corticosteroid treatment from day three to 7% months CA. Knee-ankle
length was reduced with repeat corticosteroid exposure up to three months following birth,
compared with placebo. Head circumference z-scores were unaffected by repeat
X
corticosteroid treatment from birth to lYq months CA. Repeat corticosteroids reduced
personal-social development at eight, but not four months CA, compared with placebo
Repeat corticosteroids did not reduce communication, gross motor, fine motor and problem
solving scores at four or eight months CA, did not increase the number of infants screened at
risk of developmental delay and did not reduce novelty preference, compared with placebo
Conclusions
Repeat prenatal corticosteroids reduce weight, length and knee-ankle length at birth, although
only infant weight remained reduced at 7% months CA. No adverse effects on infant
neurodevelopment were seen for repeat corticosteroid treated infants, apart from a reductio.n
in personal-social development at eight months CA. Confirmation of and further assessment
as to the long-term consequences ofthese observed effects is required.
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